Nucleoside reverse transcriptase inhibitors (NRTIs) are inexpensive FDA-approved drugs that stop HIV by blocking a critical step in HIV life cycle called reverse transcription, a process critical for HIV to replicate its genome. This collaborative research shows that NRTIs also block the activity of a biological pathway responsible for activating inflammatory processes in the body caused by a large protein complex called the NLRP3 inflammasome. According to this collaborative work, repurposing of NRTIs could be used for the treatment of age-related macular degeneration (AMD), as well as other inflammatory disorders.
